Investigation for the effect of Tapros ophthalmic solution monotherapy on the bacterial flora of conjunctival sacs

Investigation for the effect of Tapros ophthalmic solution monotherapy on the bacterial flora of conjunctival sacs - Investigation for the effect of Tapros ophthalmic solution monotherapy on the bacterial flora of conjunctival sacs

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032397

Enrollment

Registered

2018-05-10

Start date

2018-02-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma, ocular hypertension

Interventions

Tapros ophthalmic solution monotherapy for a year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Glaucoma or ocular hypertension patients who have not used other IOP-lowering drugs.

Exclusion criteria

Exclusion criteria: 1) patients who used antibiotic ophthalmic solutions within the last year 2) patients who is using ophthalmic solutions containing benzalkonium chloride 3) patients who doctors judged improper

Design outcomes

Primary

Measure	Time frame
Minimum inhibitory concentrations and Qac genes in staphylococcus epidermidis isolated from conjunctival sacs.	—

Countries

Japan

Contacts

Public ContactJinhee Lee

Miyata Eye Hospital Ophthalmology

jri-tky@umin.ac.jp0986-22-1441

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026